Pacira BioSciences Community
Our community narratives are driven by numbers and valuation.
Value any stock for free in seconds
Get alerts and valuation updates
Participate in discussions
WA
Based on Analyst Price Targets
Decisive Partnerships And Innovative Therapies Promise Growth Amidst Challenges
Key Takeaways Implementation of NOPAIN policy and new J-code could boost EXPAREL access and revenue growth. Strategic partnerships and product development, including ZILRETTA and iovera°, enhance market opportunities and future earnings potential.
View narrativeUS$18.00
FV
2.5% undervalued intrinsic discount0.73%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
5 days ago author updated this narrative